195 related articles for article (PubMed ID: 38077374)
1. Extracellular matrix complexity in biomarker studies: a novel assay detecting total serum tenascin-C reveals different distribution to isoform-specific assays.
Ozanne J; Lewis M; Schwenzer A; Kurian D; Brady J; Pritchard D; McLachlan G; Farquharson C; Midwood KS
Front Immunol; 2023; 14():1275361. PubMed ID: 38077374
[TBL] [Abstract][Full Text] [Related]
2. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.
Schwenzer A; Jiang X; Mikuls TR; Payne JB; Sayles HR; Quirke AM; Kessler BM; Fischer R; Venables PJ; Lundberg K; Midwood KS
Ann Rheum Dis; 2016 Oct; 75(10):1876-83. PubMed ID: 26659718
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing controls cell lineage-specific responses to endogenous innate immune triggers within the extracellular matrix.
Giblin SP; Schwenzer A; Midwood KS
Matrix Biol; 2020 Nov; 93():95-114. PubMed ID: 32599145
[TBL] [Abstract][Full Text] [Related]
4. Analysis of combinatorial variability reveals selective accumulation of the fibronectin type III domains B and D of tenascin-C in injured brain.
Dobbertin A; Czvitkovich S; Theocharidis U; Garwood J; Andrews MR; Properzi F; Lin R; Fawcett JW; Faissner A
Exp Neurol; 2010 Sep; 225(1):60-73. PubMed ID: 20451518
[TBL] [Abstract][Full Text] [Related]
5. Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.
Franz M; Brehm BR; Richter P; Gruen K; Neri D; Kosmehl H; Hekmat K; Renner A; Gummert J; Figulla HR; Berndt A
J Mol Histol; 2010 Feb; 41(1):39-50. PubMed ID: 20232238
[TBL] [Abstract][Full Text] [Related]
6. Expression of tenascin-C splice variants by human skin cells.
Latijnhouwers MA; de Jongh GJ; Bergers M; de Rooij MJ; Schalkwijk J
Arch Dermatol Res; 2000 Sep; 292(9):446-54. PubMed ID: 11000288
[TBL] [Abstract][Full Text] [Related]
7. Tenascin-C: Form versus function.
Giblin SP; Midwood KS
Cell Adh Migr; 2015; 9(1-2):48-82. PubMed ID: 25482829
[TBL] [Abstract][Full Text] [Related]
8. Raised circulating tenascin-C in rheumatoid arthritis.
Page TH; Charles PJ; Piccinini AM; Nicolaidou V; Taylor PC; Midwood KS
Arthritis Res Ther; 2012 Nov; 14(6):R260. PubMed ID: 23193984
[TBL] [Abstract][Full Text] [Related]
9. Embracing the complexity of matricellular proteins: the functional and clinical significance of splice variation.
Viloria K; Hill NJ
Biomol Concepts; 2016 May; 7(2):117-32. PubMed ID: 27135623
[TBL] [Abstract][Full Text] [Related]
10. Tenascin mRNA isoforms in the developing mouse brain.
Dörries U; Schachner M
J Neurosci Res; 1994 Feb; 37(3):336-47. PubMed ID: 7513764
[TBL] [Abstract][Full Text] [Related]
11. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases.
Siri A; Knäuper V; Veirana N; Caocci F; Murphy G; Zardi L
J Biol Chem; 1995 Apr; 270(15):8650-4. PubMed ID: 7536739
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.
Brack SS; Silacci M; Birchler M; Neri D
Clin Cancer Res; 2006 May; 12(10):3200-8. PubMed ID: 16707621
[TBL] [Abstract][Full Text] [Related]
13. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis.
Hasegawa M; Nakoshi Y; Muraki M; Sudo A; Kinoshita N; Yoshida T; Uchida A
J Orthop Res; 2007 May; 25(5):563-8. PubMed ID: 17262825
[TBL] [Abstract][Full Text] [Related]
14. Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading.
Ambort D; Brellier F; Becker-Pauly C; Stöcker W; Andrejevic-Blant S; Chiquet M; Sterchi EE
Matrix Biol; 2010 Jan; 29(1):31-42. PubMed ID: 19748582
[TBL] [Abstract][Full Text] [Related]
15. Tenascin-C at a glance.
Midwood KS; Chiquet M; Tucker RP; Orend G
J Cell Sci; 2016 Dec; 129(23):4321-4327. PubMed ID: 27875272
[TBL] [Abstract][Full Text] [Related]
16. Tenascin-C and carcinoma cell invasion in oral and urinary bladder cancer.
Berndt A; Richter P; Kosmehl H; Franz M
Cell Adh Migr; 2015; 9(1-2):105-11. PubMed ID: 25793577
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of extracellular matrix in periodontitis: gingipains differentially affect cell adhesion activities of fibronectin and tenascin-C.
Ruggiero S; Cosgarea R; Potempa J; Potempa B; Eick S; Chiquet M
Biochim Biophys Acta; 2013 Apr; 1832(4):517-26. PubMed ID: 23313574
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins.
Day JM; Olin AI; Murdoch AD; Canfield A; Sasaki T; Timpl R; Hardingham TE; Aspberg A
J Biol Chem; 2004 Mar; 279(13):12511-8. PubMed ID: 14722076
[TBL] [Abstract][Full Text] [Related]
19. Opposite effect of fluticasone and salmeterol on fibronectin and tenascin-C expression in primary human lung fibroblasts.
Degen M; Goulet S; Ferralli J; Roth M; Tamm M; Chiquet-Ehrismann R
Clin Exp Allergy; 2009 May; 39(5):688-99. PubMed ID: 19309351
[TBL] [Abstract][Full Text] [Related]
20. Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system.
Joester A; Faissner A
J Biol Chem; 1999 Jun; 274(24):17144-51. PubMed ID: 10358070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
